DK173382B1 - Hidtil ukendte heterokonjugater og bispecifikke antistoffer - Google Patents

Hidtil ukendte heterokonjugater og bispecifikke antistoffer Download PDF

Info

Publication number
DK173382B1
DK173382B1 DK198901594A DK159489A DK173382B1 DK 173382 B1 DK173382 B1 DK 173382B1 DK 198901594 A DK198901594 A DK 198901594A DK 159489 A DK159489 A DK 159489A DK 173382 B1 DK173382 B1 DK 173382B1
Authority
DK
Denmark
Prior art keywords
heteroconjugate
antigen
antibody
cells
reactive
Prior art date
Application number
DK198901594A
Other languages
Danish (da)
English (en)
Other versions
DK159489A (da
DK159489D0 (da
Inventor
Jeffrey A Ledbetter
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of DK159489D0 publication Critical patent/DK159489D0/da
Publication of DK159489A publication Critical patent/DK159489A/da
Application granted granted Critical
Publication of DK173382B1 publication Critical patent/DK173382B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Coating With Molten Metal (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK198901594A 1988-04-04 1989-04-03 Hidtil ukendte heterokonjugater og bispecifikke antistoffer DK173382B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17682588A 1988-04-04 1988-04-04
US17682588 1988-04-04
US27193488A 1988-11-14 1988-11-14
US27193488 1988-11-14

Publications (3)

Publication Number Publication Date
DK159489D0 DK159489D0 (da) 1989-04-03
DK159489A DK159489A (da) 1989-10-05
DK173382B1 true DK173382B1 (da) 2000-09-11

Family

ID=26872636

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198901594A DK173382B1 (da) 1988-04-04 1989-04-03 Hidtil ukendte heterokonjugater og bispecifikke antistoffer

Country Status (20)

Country Link
EP (1) EP0336379B1 (de)
JP (1) JP2613106B2 (de)
KR (1) KR100205833B1 (de)
CN (1) CN1058296C (de)
AT (1) ATE133866T1 (de)
AU (1) AU629204B2 (de)
DE (1) DE68925593T2 (de)
DK (1) DK173382B1 (de)
ES (1) ES2083960T3 (de)
FI (1) FI105320B (de)
GR (1) GR3019224T3 (de)
HU (1) HU213576B (de)
IE (1) IE72187B1 (de)
IL (1) IL89823A (de)
MY (1) MY106592A (de)
NO (1) NO178699C (de)
NZ (1) NZ228560A (de)
PT (1) PT90195B (de)
YU (1) YU68589A (de)
ZA (1) ZA892448B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
WO1991003493A1 (en) * 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JPH05268986A (ja) * 1990-03-19 1993-10-19 Bristol Myers Squibb Co モノクローナル抗体及びリンパ球の活性法
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
ES2125248T3 (es) * 1992-04-10 1999-03-01 Thomas Totterman Metodo de deteccion de una infeccion cmv.
US5635602A (en) * 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995030014A1 (en) 1994-05-02 1995-11-09 Ciba-Geigy Ag Bifunctional protein, preparation and use
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
EP0945139A1 (de) * 1998-03-23 1999-09-29 Katholieke Universiteit Nijmegen Verfahren un Mitteln zur Herstellung von Immunkrankheiten wie Graft-Versus-Host-Krankheit
EP1189635A4 (de) * 1999-06-17 2003-04-23 Univ Vermont Autologe adoptive immuntherapie mit t-zellen oder b-zellenb, welche antigen-spezifisch sensibilisiert wurden
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
JP4381140B2 (ja) * 2001-10-12 2009-12-09 シェーリング コーポレイション 免疫応答を調節するための二重特異性抗体の使用
GB0305702D0 (en) * 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
WO2021160267A1 (en) * 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4378529A1 (de) * 2022-12-03 2024-06-05 Universitätsklinikum Hamburg-Eppendorf Antikörper zur verwendung in einer therapie mit effektorzell-engagement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
EP0153871A3 (de) * 1984-03-01 1987-07-01 Centocor, Inc. Steigerung der Antigenimmunogenität mittels Antikörper
DE3583278D1 (de) * 1984-04-23 1991-07-25 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
CA1338518C (en) * 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells

Also Published As

Publication number Publication date
DK159489A (da) 1989-10-05
AU3242389A (en) 1989-10-05
EP0336379A3 (en) 1990-01-31
PT90195B (pt) 1994-06-30
PT90195A (pt) 1989-11-10
HU213576B (en) 1997-08-28
JP2613106B2 (ja) 1997-05-21
EP0336379B1 (de) 1996-02-07
MY106592A (en) 1995-06-30
DE68925593T2 (de) 1996-06-13
NZ228560A (en) 1991-10-25
NO178699B (no) 1996-02-05
ZA892448B (en) 1989-12-27
ES2083960T3 (es) 1996-05-01
AU629204B2 (en) 1992-10-01
GR3019224T3 (en) 1996-06-30
ATE133866T1 (de) 1996-02-15
CN1036988A (zh) 1989-11-08
JPH01304356A (ja) 1989-12-07
CN1058296C (zh) 2000-11-08
KR100205833B1 (ko) 1999-07-01
DE68925593D1 (de) 1996-03-21
NO891375L (no) 1989-10-05
IL89823A (en) 1994-07-31
FI891528A (fi) 1989-10-05
IE72187B1 (en) 1997-03-26
IL89823A0 (en) 1989-12-15
KR890015751A (ko) 1989-11-25
NO178699C (no) 1996-05-15
FI105320B (fi) 2000-07-31
DK159489D0 (da) 1989-04-03
YU68589A (en) 1991-10-31
NO891375D0 (no) 1989-03-31
FI891528A0 (fi) 1989-03-30
HUT51338A (en) 1990-04-28
EP0336379A2 (de) 1989-10-11
IE891054L (en) 1989-10-04

Similar Documents

Publication Publication Date Title
DK173382B1 (da) Hidtil ukendte heterokonjugater og bispecifikke antistoffer
US6010902A (en) Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
Lanier et al. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes.
US7144575B2 (en) Methods for selectively stimulating proliferation of T cells
US6887466B2 (en) Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) Methods for selectively stimulating proliferation of T cells
KR20170134331A (ko) 조작된 면역 세포들의 분류/소모를 위한 mAb-주도의 키메라 항원 수용체 시스템들
JP5154949B2 (ja) ウイルス感染を治療するための組成物および方法
US20220064255A1 (en) Anti-tcr antibody molecules and uses thereof
CA3110905A1 (en) Chimeric antigen receptors against multiple hla-g isoforms
NO337619B1 (no) Sammensetning for å øke effektiviteten til terapeutiske antistoffer ved anvendelse av NK-cellepotensierende sammensetninger
De Jong et al. Regulation of T-cell differentiation by CD2 and CD28 accessory molecules.
Tian et al. HIV envelope-directed signaling aberrancies and cell death of CD4+ T cells in the absence of TCR co-stimulation
CN114369168B (zh) 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法
Van Lier et al. Studies on the monocyte dependence of T-cell proliferation induced by monoclonal antibodies directed against regions I and II of the CD2 antigen.
Hansson et al. MHC nonrestricted cytotoxic T cell clones with selective specificity from patients with transitional cell carcinoma (TCC) of the urinary bladder
EP4378953A1 (de) Auf cd229 abzielende einheit zur behandlung von cd229-positivem krebs
AU765876B2 (en) Methods for selectively stimulating proliferation of T cells
Leeuwenberg Functional studies on monoclon antibodies directed against the
Leeuwenberg Functional studies on monoclonal antibodies directed against the T cell differentiation antigens CD3 and CD7
Bishoff Natural killer lymphocyte membrane antigens involved in allorecognition
Forman et al. Immune Privilege and Tolerance–Therapeutic Antibody Approaches
Rosenzweig Immune Privilege and Tolerance-Therapeutic Antibody Approaches
DD295312A5 (de) Verfahren zur diagnostizierung eines defektes in der cd-rezeptorfunktion von patienten, welche an einer krankheit leiden, die eine t-zellen-fehlregulation oder funktionsstoerung beinhaltet
AU8948798A (en) Methods for selectively stimulating proliferation of T cells

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK